Baxter International said that it has closed its acquisition of Baxa Corp., a company that makes technology to improve the preparation and delivery of oral and IV dose drugs.
Baxter completes Baxa acquisition
Baxter paid $380 million in cash for Englewood, Colo.-based Baxa, according to a news release. The deal was announced in August.
“The acquisition of Baxa demonstrates Baxter's long-term commitment to nutrition and patient safety and it allows us to offer a broader range of solutions for the safe preparation and delivery of IV medications,” said Robert Davis, president of Baxter's medical products business, in the news release.
Baxa reported $157 million in annual sales in 2010.
Send us a letter
Have an opinion about this story? Click here to submit a Letter to the Editor, and we may publish it in print.